Mark J. O'Connor

Molecular Biology · 2006–2017

A researcher in the Science corpus: 6 papers; trusts 18 researchers and is trusted by 5 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 97 citations into it; #5,979 of 17,773 by trust here, #3,584 by citations
• Oncology — 73 citations into it; #349 of 1,698 by trust here, #352 by citations
• Cancer Research — 17 citations into it
• Cell Biology — 17 citations into it
• Physiology — 8 citations into it

Whom Mark J. O'Connor trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Yves Pommier
2. Jan H. J. Hoeijmakers
3. Alan Ashworth
4. N. Curtin
5. Thomas Helleday
6. Karlene A. Cimprich
7. W. Kaelin
8. J. Jiricny
9. M. Lieber
10. Raphael Ceccaldi

Who trusts Mark J. O'Connor overall

1. Yves Pommier
2. J. D. de Bono
3. Andrew N. Blackford
4. Stephen P. Jackson

Papers from Mark J. O'Connor's perspective

Ordered by how strongly the researchers Mark J. O'Connor trusts endorse each paper. Same corpus, a different order for every researcher.

1. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy (Nature)
2. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks (Cell)
3. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase (Nature)
4. Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse (EMBO Journal)
5. Review Cancer Susceptibility and the Functions of BRCA1 and BRCA2
6. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. (The Lancet Oncology)
7. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs (Proceedings of the National Academy of Sciences of the United States of America)
8. DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs (Chemistry and Biology)
9. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer (New England Journal of Medicine)
10. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer (Nature Genetics)

Their papers

• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. (2009) — 3,580 citations
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. (2006) — 1,299 citations
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs (2008) — 962 citations
• Targeting the DNA Damage Response in Cancer. (2015) — 1,398 citations
• ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1 (2017) — 83 citations
• Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action (2016) — 665 citations